Relay Therapeutics Inc [RLAY] stock is trading at $3.18, up 6.00%. It is a good measure of the stock’s recent performance to check whether the stock’s short-term value is rising or falling. The RLAY shares have gain 9.28% over the last week, with a monthly amount drifted -3.34%, and not seem to be holding up well over a long-time horizon.
From an analyst’s perspective:
Relay Therapeutics Inc [NASDAQ: RLAY] stock has seen the most recent analyst activity on April 17, 2025, when Wells Fargo initiated its Equal Weight rating and assigned the stock a price target of $4. Previously, Jefferies upgraded its rating to Buy on September 10, 2024, and elevated its price target to $16. Oppenheimer downgraded its rating to a Perform. Barclays upgraded its rating to a Overweight but $15 remained the price target by the analyst firm on May 10, 2024. Jefferies upgraded its rating to Hold for this stock on April 20, 2023, but kept the price target unchanged to $12.50. In a note dated April 19, 2023, Raymond James upgraded an Strong Buy rating on this stock but restated the target price of $29.
Relay Therapeutics Inc [RLAY] stock has fluctuated between $1.77 and $10.72 over the past year. Currently, Wall Street analysts expect the stock to reach $19.4 within the next 12 months. Relay Therapeutics Inc [NASDAQ: RLAY] shares were valued at $3.18 at the most recent close of the market. An investor can expect a potential return of 510.06% based on the average RLAY price forecast.
Analyzing the RLAY fundamentals
Relay Therapeutics Inc [NASDAQ:RLAY] reported sales of 7.68M for the trailing twelve months, which represents a drop of -23.26%. Gross Profit Margin for this corporation currently stands at -0.12% with Operating Profit Margin at -49.27%, Pretax Profit Margin comes in at -43.42%, and Net Profit Margin reading is -43.42%. To continue investigating profitability, this company’s Return on Assets is posted at -0.42, Equity is -0.44 and Total Capital is -0.5. An extended analysis of the company’s primary financial structure reveals a debt-to-equity ratio of0.07.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 3.01 points at the first support level, and at 2.83 for the second support level. However, for the 1st resistance point, the stock is sitting at 3.28, and for the 2nd resistance point, it is at 3.38.
Ratios To Look Out For
For context, Relay Therapeutics Inc’s Current Ratio is 19.96. Further, the Quick Ratio stands at 19.96, while the Cash Ratio is 2.52. Considering the valuation of this stock, the price to sales ratio is 70.99, the price to book ratio is 0.75.
Transactions by insiders
Recent insider trading involved Rahmer Peter, that happened on Apr 30 ’25 when 10739.0 shares were sold., Rahmer Peter completed a deal on Apr 28 ’25 to sell 1364.0 shares. Meanwhile, Chief Financial Officer Catinazzo Thomas sold 12943.0 shares on Apr 30 ’25.
